Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 151 articles:
HTML format
Text format



Single Articles


    November 2017
  1. WINSLOW UC, Nordestgaard BG, Afzal S
    High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of 97849 individuals.
    Br J Dermatol. 2017 Nov 16. doi: 10.1111/bjd.16127.
    PubMed     Text format     Abstract available


  2. DEL PUERTO C, Navarrete-Dechent C, Molgo M, Camargo CA Jr, et al
    Immunohistochemical expression of vitamin D receptor in melanocytic nevi and cutaneous melanoma. A case-control study.
    Br J Dermatol. 2017 Nov 6. doi: 10.1111/bjd.16103.
    PubMed     Text format     Abstract available


    October 2017
  3. TRAN AD, Fogarty G, Nowak AK, Espinoza D, et al
    A systematic review and meta-analysis of utility estimates in melanoma.
    Br J Dermatol. 2017 Oct 27. doi: 10.1111/bjd.16098.
    PubMed     Text format     Abstract available


  4. SEO JW, Ha SM, Song KH
    Insulin-Like Growth Factor-II mRNA-Binding Protein 3 as a Novel Prognostic Biomarker for Acral Lentiginous Melanoma.
    Br J Dermatol. 2017 Oct 19. doi: 10.1111/bjd.16077.
    PubMed     Text format     Abstract available


  5. BASSOLI S, Kyrgidis A, Ciardo S, Casari A, et al
    Uncovering the diagnostic dermoscopic features of flat melanomas located on the lower limbs.
    Br J Dermatol. 2017 Oct 7. doi: 10.1111/bjd.16030.
    PubMed     Text format     Abstract available


  6. SCHAIDER H, Sturm RA
    The evolving universe of BRAF mutations in melanoma.
    Br J Dermatol. 2017;177:893.
    PubMed     Text format    


  7. ROBINSON JK, Spring B
    Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family.
    Br J Dermatol. 2017;177:890-891.
    PubMed     Text format    


    September 2017
  8. SATTLER EC, Ertl-Wagner B, Pellegrini C, Peris K, et al
    Cutaneous melanoma in Birt-Hogg-Dube syndrome - part of the clinical spectrum?
    Br J Dermatol. 2017 Sep 4. doi: 10.1111/bjd.15937.
    PubMed     Text format     Abstract available


  9. ZNAOR A
    Melanoma burden, healthcare utilization and the potential for overdiagnosis in the elderly U.S. population.
    Br J Dermatol. 2017;177:625.
    PubMed     Text format    


    August 2017
  10. YOULDEN DR, Baade PD, Aitken JF, Green AC, et al
    Prognostic importance of a second invasive primary melanoma according to tumor stage.
    Br J Dermatol. 2017 Aug 3. doi: 10.1111/bjd.15863.
    PubMed     Text format     Abstract available


  11. BERK-KRAUSS J, Stein JA
    The role of access to care in acral lentiginous melanoma survival.
    Br J Dermatol. 2017;177:341-342.
    PubMed     Text format    


  12. HILL D, Lovat P
    Cover Image: Invasion of a cutaneous melanoma tumour.
    Br J Dermatol. 2017;177:599.
    PubMed     Text format    


    July 2017
  13. ADLER NR, Kelly JW, Haydon A, McLean CA, et al
    Clinicopathological characteristics and prognosis of patients with multiple primary melanomas.
    Br J Dermatol. 2017 Jul 28. doi: 10.1111/bjd.15855.
    PubMed     Text format     Abstract available


  14. DIAS-SANTAGATA D, Selim MA, Su Y, Peng Y, et al
    KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15836.
    PubMed     Text format     Abstract available


  15. TERAMOTO Y, Keim U, Gesierich A, Schuler G, et al
    Acral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.
    Br J Dermatol. 2017 Jul 14. doi: 10.1111/bjd.15803.
    PubMed     Text format     Abstract available


  16. GIBBS DC, Ward SV, Orlow I, Cadby G, et al
    Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
    Br J Dermatol. 2017 Jul 1. doi: 10.1111/bjd.15784.
    PubMed     Text format     Abstract available


  17. MAHER NG, Guitera P
    Imiquimod treatment for lentigo maligna: LIMIT-1 trial.
    Br J Dermatol. 2017;177:324-325.
    PubMed     Text format    


    June 2017
  18. SMIT AK, Keogh LA, Newson AJ, Butow PN, et al
    Does personalised melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?
    Br J Dermatol. 2017 Jun 19. doi: 10.1111/bjd.15744.
    PubMed     Text format     Abstract available


  19. KIM SK, Barker CA
    Outcomes of radiation therapy for advanced T3/T4 non-melanoma cutaneous squamous cell and basal cell carcinoma.
    Br J Dermatol. 2017 Jun 15. doi: 10.1111/bjd.15728.
    PubMed     Text format     Abstract available


  20. CERIO R, Moir G
    Palliative electrochemotherapy treatment of metastatic malignant melanoma.
    Br J Dermatol. 2017;176:1427.
    PubMed     Text format    


  21. JONES G
    Methotrexate increases the risk of melanoma: or does it?
    Br J Dermatol. 2017;176:1429-1430.
    PubMed     Text format    


    May 2017
  22. RIBERO S, Carrera C, Tell-Marti G, Pastorino C, et al
    Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study.
    Br J Dermatol. 2017 May 27. doi: 10.1111/bjd.15687.
    PubMed     Text format     Abstract available


  23. SWETTER SM
    Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard?
    Br J Dermatol. 2017;176:1115-1116.
    PubMed     Text format    


  24. ELLIS RA
    T-type calcium channels as potential biomarkers in melanoma.
    Br J Dermatol. 2017;176:1122.
    PubMed     Text format    


  25. KRENGEL S, Reyes-Mugica M
    Melanoma risk in congenital melanocytic naevi.
    Br J Dermatol. 2017;176:1114.
    PubMed     Text format    


    April 2017
  26. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease: reply from authors.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15626.
    PubMed     Text format     Abstract available


  27. SALEH DB
    RE: Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15619.
    PubMed     Text format     Abstract available


  28. ASGARI MM, Shen L, Sokil MM, Yeh I, et al
    Prognostics factors and survival in acral lentiginous melanoma.
    Br J Dermatol. 2017 Apr 22. doi: 10.1111/bjd.15600.
    PubMed     Text format     Abstract available


  29. GUALANO MR, Osella-Abate S, Scaioli G, Marra E, et al
    Prognostic role of Histologic regression in primary cutaneous melanoma: A Systematic Review and Meta-analysis.
    Br J Dermatol. 2017 Apr 7. doi: 10.1111/bjd.15552.
    PubMed     Text format     Abstract available


  30. NIJSTEN T, Wakkee M
    The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where?
    Br J Dermatol. 2017;176:839-841.
    PubMed     Text format    


  31. MONTAUDIE H, Pradelli J, Passeron T, Lacour JP, et al
    Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Br J Dermatol. 2017;176:1060-1063.
    PubMed     Text format     Abstract available


    March 2017
  32. LOTT JP, Wang Q, Titus LJ, Onega T, et al
    Temporal Trends in Healthcare Utilization following Primary Melanoma Diagnosis among Medicare Beneficiaries.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15530.
    PubMed     Text format     Abstract available


  33. KARIMKHANI C, Green AC, Nijsten T, Weinstock MA, et al
    The Global Burden of Melanoma: Results from Global Burden of Disease Study 2015.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15510.
    PubMed     Text format     Abstract available


  34. KOGUCHI-YOSHIOKA H, Okiyama N, Iwamoto K, Matsumura Y, et al
    Intravenous immunoglobulin contributes to control anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis with palmar violaceous macules/papules.
    Br J Dermatol. 2017 Mar 27. doi: 10.1111/bjd.15499.
    PubMed     Text format     Abstract available


  35. LICCIARDELLO M, T Giura M, Rozzo G, Marra E, et al
    Arrhythmias in metastatic melanoma patient treated with targeted therapy and ICD implant.
    Br J Dermatol. 2017 Mar 10. doi: 10.1111/bjd.15447.
    PubMed     Text format     Abstract available


  36. RICHTIG G, Hoeller C, Kashofer K, Aigelsreiter A, et al
    Beyond the BRAFV600E hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients.
    Br J Dermatol. 2017 Mar 9. doi: 10.1111/bjd.15436.
    PubMed     Text format     Abstract available


    February 2017
  37. CORR M, Roulston G, King N, Dornan T, et al
    Living with 'melanoma'...for a day: a phenomenological analysis of medical students' simulated experiences.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15402.
    PubMed     Text format     Abstract available


  38. JORDAN M, Ghoreschi K
    Anti-melanoma differentiation-associated protein 5 autoantibodies as a marker for dermatomyositis-associated interstitial lung disease.
    Br J Dermatol. 2017;176:294-295.
    PubMed     Text format    


    January 2017
  39. WOLNER ZJ, Marghoob AA, Pulitzer MP, Postow MA, et al
    A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
    Br J Dermatol. 2017 Jan 28. doi: 10.1111/bjd.15354.
    PubMed     Text format     Abstract available


  40. VANHAECKE C, Deilhes F, Chanal J, Regnier-Rosencher E, et al
    BRAFV600 inhibitor discontinuation after complete response in advanced melanoma. A retrospective analysis of 16 patients.
    Br J Dermatol. 2017 Jan 27. doi: 10.1111/bjd.15345.
    PubMed     Text format     Abstract available


  41. KUNTE C, Letule V, Gehl J, Dahlstroem K, et al
    Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15340.
    PubMed     Text format     Abstract available


  42. MINAGAWA A, Omodaka T, Koga H, Yokokawa Y, et al
    Nail apparatus melanoma thickness is associated with side and age.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15318.
    PubMed     Text format     Abstract available


  43. KINSLER VA, O'Hare P, Bulstrode N, Calonje JE, et al
    Melanoma in congenital melanocytic naevi.
    Br J Dermatol. 2017 Jan 12. doi: 10.1111/bjd.15301.
    PubMed     Text format     Abstract available


    December 2016
  44. NEITTAANMAKI N, Salmivuori M, Polonen I, Jeskanen L, et al
    Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15267.
    PubMed     Text format     Abstract available


  45. USHER-SMITH JA, Kassianos AP, Emery JD, Abel GA, et al
    Identifying people at higher risk of melanoma across the U.K.: a primary-care-based electronic survey.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15181.
    PubMed     Text format     Abstract available


  46. RICHTIG G, Richtig E, Kashofer K, Koch L, et al
    Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15222.
    PubMed     Text format     Abstract available


  47. LINOS E, Li WQ, Han J, Li T, et al
    Lifetime UV exposure and Lentigo Maligna Melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15218.
    PubMed     Text format     Abstract available


  48. SPENDER LC, Inman GJ
    Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.
    Br J Dermatol. 2016;175:1140-1141.
    PubMed     Text format    


  49. YELAMOS O, Nehal KS
    Integrating clinical information, dermoscopy and reflectance confocal microscopy to improve the diagnostic accuracy and confidence of amelanotic and lightly pigmented melanomas.
    Br J Dermatol. 2016;175:1147-1148.
    PubMed     Text format    


  50. HAASS NK
    JNK-ERK signalling in melanoma: rewired or entangled?
    Br J Dermatol. 2016;175:1139-1140.
    PubMed     Text format    


  51. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2016;175:1340-1341.
    PubMed     Text format    


    November 2016
  52. SPEIGL L, Janssen N, Weide B, Pawelec G, et al
    Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
    Br J Dermatol. 2016 Nov 21. doi: 10.1111/bjd.15194.
    PubMed     Text format     Abstract available


  53. MAHER NG, Blumetti TP, Gomes EE, Cheng HM, et al
    Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions.
    Br J Dermatol. 2016 Nov 18. doi: 10.1111/bjd.15187.
    PubMed     Text format     Abstract available


  54. POLESIE S, Gillstedt M, Sonnergren HH, Osmancevic A, et al
    Methotrexate Treatment and Risk for Cutaneous Malignant Melanoma - a Retrospective Comparative Registry-based Cohort Study.
    Br J Dermatol. 2016 Nov 10. doi: 10.1111/bjd.15170.
    PubMed     Text format     Abstract available


  55. BARRETT JH
    Telomere length and melanoma - is there a straightforward relationship?
    Br J Dermatol. 2016;175:865-866.
    PubMed     Text format    


  56. ELLIKER KR, Williams HC
    Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies.
    Br J Dermatol. 2016;175:851-852.
    PubMed     Text format    


  57. EISEMANN N
    Routine health data in skin cancer screening evaluation.
    Br J Dermatol. 2016;175:862.
    PubMed     Text format    


    October 2016
  58. RICHTIG G, Byrom L, Kupsa R, Schaider H, et al
    Pregnancy as driver for melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15124.
    PubMed     Text format     Abstract available


  59. MAIQUES O, Macia A, Moreno S, Barcelo C, et al
    Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15121.
    PubMed     Text format     Abstract available


  60. O'SHEA SJ, Davies JR, Newton-Bishop JA
    Vitamin D, vitamin A, the primary melanoma transcriptome and survival.
    Br J Dermatol. 2016;175 Suppl 2:30-34.
    PubMed     Text format     Abstract available


    September 2016
  61. PIZZICHETTA MA, Kittler H, Stanganelli I, Ghigliotti G, et al
    Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma.
    Br J Dermatol. 2016 Sep 28. doi: 10.1111/bjd.15093.
    PubMed     Text format     Abstract available


  62. WEINSTOCK MA, Lott JP, Wang Q, Titus LJ, et al
    Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15077.
    PubMed     Text format     Abstract available


  63. LO MC, Maraka J, Garioch J, John WG, et al
    Monitoring vitamin D in the melanoma patient - impact of sun avoidance on vitamin D levels of melanoma patients at a tertiary UK referral melanoma service.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15062.
    PubMed     Text format     Abstract available


  64. SCHUURMAN MS, de Waal AC, Thijs EJ, van Rossum MM, et al
    Risk factors for second primary melanoma among Dutch melanoma patients.
    Br J Dermatol. 2016 Sep 5. doi: 10.1111/bjd.15024.
    PubMed     Text format     Abstract available


  65. FOX J
    A changing treatment paradigm: the role of palliative care in metastatic melanoma.
    Br J Dermatol. 2016;175:462-3.
    PubMed     Text format    


    August 2016
  66. RIBERO S, Marra E, Tomasini CF, Fierro MT, et al
    Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases.
    Br J Dermatol. 2016 Aug 12. doi: 10.1111/bjd.14951.
    PubMed     Text format     Abstract available


  67. RIBERO S, Osella-Abate S, Reyes-Garcia D, Grulich A, et al
    Gender effects on naevi body distribution and melanoma risk in two melanoma case control studies at different latitudes.
    Br J Dermatol. 2016 Aug 1. doi: 10.1111/bjd.14915.
    PubMed     Text format     Abstract available


    July 2016
  68. MANGAS C, Potrony M, Mainetti C, Bianchi E, et al
    Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
    Br J Dermatol. 2016 Jul 30. doi: 10.1111/bjd.14897.
    PubMed     Text format     Abstract available


  69. WILLIS CM, Britton LE, Swindells MA, Jones EM, et al
    Invasive melanoma in-vivo can be distinguished from basal cell carcinoma, benign naevi and healthy skin by canine olfaction: a proof of principle study of differential volatile organic compound emission.
    Br J Dermatol. 2016 Jul 25. doi: 10.1111/bjd.14887.
    PubMed     Text format     Abstract available


  70. GRANT WB
    Increased risk of non-cutaneous malignancy after diagnosis of non-melanoma skin cancer may be due to sun avoidance.
    Br J Dermatol. 2016 Jul 15. doi: 10.1111/bjd.14862.
    PubMed     Text format     Abstract available


  71. PARDO LM, van der Leest RJ, de Vries E, Soerjomataram I, et al
    Comparing survival of patients with single or multiple primary melanoma in The Netherlands: 1994-2009.
    Br J Dermatol. 2016 Jul 5. doi: 10.1111/bjd.14846.
    PubMed     Text format     Abstract available


  72. KIRBY LC, Banerjee A, Augustine T, Douglas JF, et al
    An ethical dilemma: malignant melanoma in a 51-year-old patient awaiting simultaneous kidney and pancreas transplantation for type 1 diabetes.
    Br J Dermatol. 2016;175:172-4.
    PubMed     Text format     Abstract available


    June 2016
  73. SHITARA D, Tell-Marti G, Badenas C, Enokihara MM, et al
    Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry: reply from the authors.
    Br J Dermatol. 2016 Jun 16. doi: 10.1111/bjd.14613.
    PubMed     Text format    


  74. TEULINGS HE, Lommerts JE, Wolkerstorfer A, Nieuweboer-Krobotova L, et al
    Vitiligo-like depigmentations as first sign of melanoma; a retrospective case series from a tertiary vitiligo centre.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14790.
    PubMed     Text format     Abstract available


  75. WANG CC, Tang CH, Wang CY, Huang SY, et al
    Risk of skin cancer in chronic haemodialysis patients: a nationwide, population-based study in Taiwan.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14789.
    PubMed     Text format     Abstract available


  76. STEFANAKI I, Stratigos AJ
    Inherited susceptibility to melanoma: insights from a high-risk Austrian cohort.
    Br J Dermatol. 2016;174:1188-90.
    PubMed     Text format    


    May 2016
  77. RANSOHOFF KJ, Stefanick ML, Li S, Kurian AW, et al
    Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative.
    Br J Dermatol. 2016 May 26. doi: 10.1111/bjd.14766.
    PubMed     Text format     Abstract available


  78. TRAUTMANN F, Meier F, Seidler A, Schmitt J, et al
    Effects of the German skin cancer screening program on melanoma incidence and indicators of disease severity.
    Br J Dermatol. 2016 May 20. doi: 10.1111/bjd.14758.
    PubMed     Text format     Abstract available


  79. GUITERA P, Menzies SW, Argenziano G, Longo C, et al
    Dermoscopy and in vivo confocal microscopy are complimentary techniques for the diagnosis of difficult amelanotic and light colored skin lesions.
    Br J Dermatol. 2016 May 13. doi: 10.1111/bjd.14749.
    PubMed     Text format     Abstract available


  80. THURNEYSEN S, Cheng PF, Nagel HW, Kunz M, et al
    An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel.
    Br J Dermatol. 2016 May 11. doi: 10.1111/bjd.14727.
    PubMed     Text format     Abstract available


  81. MCCONNELL AT, Ellis R, Pathy B, Plummer R, et al
    The prognostic significance and impact of the CXCR4/CXCR7/CXCL12 axis in primary cutaneous melanoma.
    Br J Dermatol. 2016 May 11. doi: 10.1111/bjd.14720.
    PubMed     Text format     Abstract available


  82. PATHRIA G, Garg B, Garg K, Wagner C, et al
    Dual JNK-Cyclin D1 and ERK-c-JUN Disjunction in Human Melanoma.
    Br J Dermatol. 2016 May 5. doi: 10.1111/bjd.14713.
    PubMed     Text format     Abstract available


  83. PIANA S, Moscarella E, Longo C
    Image Gallery: Brain? no, melanoma.
    Br J Dermatol. 2016;174:e41.
    PubMed     Text format    


  84. SCHOFIELD JK, Robinson R, Reeken S, Jackson R, et al
    National Institute for Health and Care Excellence melanoma guidelines: good news for patients but challenging to implement.
    Br J Dermatol. 2016;174:949-50.
    PubMed     Text format    


  85. LLOYD-LAVERY A, Hodgson T, Coupe N, Bond S, et al
    Delayed oral toxicity from long-term vemurafenib therapy.
    Br J Dermatol. 2016;174:1159-60.
    PubMed     Text format    


  86. LALLAS A, Tschandl P, Kyrgidis A, Stolz W, et al
    Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis.
    Br J Dermatol. 2016;174:1079-85.
    PubMed     Text format     Abstract available


  87. GREVELING K, de Vries K, van Doorn MB, Prens EP, et al
    A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose.
    Br J Dermatol. 2016;174:1134-6.
    PubMed     Text format    


    April 2016
  88. MENIN C, Bojnik E, Del Bianco P, Elefanti L, et al
    Differences in telomere length between sporadic and familial cutaneous melanoma.
    Br J Dermatol. 2016 Apr 7. doi: 10.1111/bjd.14652.
    PubMed     Text format     Abstract available


  89. GALLAIS SEREZAL I, Beaussant Y, Rochigneux P, Tournigand C, et al
    End-of-life care for hospitalised patients with metastatic melanoma in France: a nationwide, register-based study.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14631.
    PubMed     Text format     Abstract available


  90. HORSHAM C, J Loescher L, Whiteman DC, Soyer HP, et al
    Consumer acceptance of patient-performed mobile teledermoscopy for the early detection of melanoma.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14630.
    PubMed     Text format     Abstract available


  91. OREGAARD JS, Jarjis RD, Venzo A, Jemec B, et al
    Cover Image: Unique presentation of a subungual malignant melanoma in situ.
    Br J Dermatol. 2016;174:935.
    PubMed     Text format    


  92. SULLIVAN RJ
    Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.
    Br J Dermatol. 2016;174:716-7.
    PubMed     Text format    


  93. BAADE PD
    Quantifying the mortality burden for skin cancers other than melanoma.
    Br J Dermatol. 2016;174:713-4.
    PubMed     Text format    


  94. NILSEN LT, Hannevik M, Veierod MB
    Ultraviolet exposure from indoor tanning devices: a systematic review.
    Br J Dermatol. 2016;174:730-40.
    PubMed     Text format     Abstract available


    March 2016
  95. UGUEN A
    Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry.
    Br J Dermatol. 2016 Mar 31. doi: 10.1111/bjd.14603.
    PubMed     Text format     Abstract available


  96. PARKINS G, Brown E, Gupta G
    Radiological imaging in all stage III melanoma- current practice in the United Kingdom.
    Br J Dermatol. 2016 Mar 15. doi: 10.1111/bjd.14551.
    PubMed     Text format     Abstract available


  97. PARTARRIEU-MEJIAS F, Perez-Velasquez F
    Image Gallery: Xeroderma pigmentosum.
    Br J Dermatol. 2016;174:e12.
    PubMed     Text format    


  98. DE VRIES K, Greveling K, Prens LM, Munte K, et al
    Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision.
    Br J Dermatol. 2016;174:588-93.
    PubMed     Text format     Abstract available


  99. BELLON T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, et al
    Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Br J Dermatol. 2016;174:621-4.
    PubMed     Text format     Abstract available


    February 2016
  100. CHAPPUIS P, Duru G, Marchal O, Girier P, et al
    Dermoscopy: A useful tool for general practitioners in melanoma screening: A nationwide survey.
    Br J Dermatol. 2016 Feb 23. doi: 10.1111/bjd.14495.
    PubMed     Text format     Abstract available


  101. STASER K, Chen D, Solus J, Rosman IS, et al
    Extensive tumoral melanosis associated with ipilimumab-treated melanoma.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14474.
    PubMed     Text format     Abstract available


  102. SARGEN MR, Merrill SL, Chu EY, Nathanson KL, et al
    CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic nevi, and internal malignancies: A case series and review of the literature.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14485.
    PubMed     Text format     Abstract available


  103. NALDI L, Cazzaniga S
    Prediction of high total naevus count to estimate melanoma risk. We need more, don't we?
    Br J Dermatol. 2016;174:261-2.
    PubMed     Text format    


  104. LEE S, Duffy DL, McClenahan P, Lee KJ, et al
    Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study.
    Br J Dermatol. 2016;174:356-63.
    PubMed     Text format     Abstract available


    January 2016
  105. MULLER C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al
    Characterization of high risk melanoma patients in Austria.
    Br J Dermatol. 2016 Jan 22. doi: 10.1111/bjd.14407.
    PubMed     Text format     Abstract available


  106. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.
    Br J Dermatol. 2016 Jan 20. doi: 10.1111/bjd.14279.
    PubMed     Text format    


  107. CHMIELOWSKI B
    Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.
    Br J Dermatol. 2016;174:20.
    PubMed     Text format    


  108. CLIFF SH
    Five-year recurrence rate of lentigo maligna after off-label treatment with imiquimod.
    Br J Dermatol. 2016;174:22-3.
    PubMed     Text format    


  109. KAI AC, Richards T, Coleman A, Mallipeddi R, et al
    Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
    Br J Dermatol. 2016;174:165-8.
    PubMed     Text format     Abstract available


    December 2015
  110. FERNANDEZ-VEGA I, Santos-Juanes J, Fresno-Forcelledo MF
    Primary amelanotic rhabdoid melanoma of the forehead.
    Br J Dermatol. 2015 Dec 29. doi: 10.1111/bjd.14382.
    PubMed     Text format     Abstract available


  111. ROACH RE, Plasmeijer EI, van Doorn R, Bergman W, et al
    The value of clinical characteristics for the diagnosis of melanoma in patients presenting at a pigmented lesion clinic.
    Br J Dermatol. 2015 Dec 26. doi: 10.1111/bjd.14375.
    PubMed     Text format     Abstract available


  112. EISEMANN N, Jansen L, Castro FA, Chen T, et al
    Survival from non-melanoma skin cancer in Germany.
    Br J Dermatol. 2015 Dec 16. doi: 10.1111/bjd.14352.
    PubMed     Text format     Abstract available


  113. FRAUCHIGER AL, Mangana J, Rechsteiner M, Moch H, et al
    Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status.
    Br J Dermatol. 2015 Dec 13. doi: 10.1111/bjd.14347.
    PubMed     Text format     Abstract available


  114. CURL PK
    Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment.
    Br J Dermatol. 2015;173:1365-6.
    PubMed     Text format    


  115. MILLINGTON GW
    Growth and hormonal profiling in children with congenital melanocytic naevi.
    Br J Dermatol. 2015;173:1366-7.
    PubMed     Text format    


    November 2015
  116. TSCHANDL P, Berghoff AS, Preusser M, Pammer J, et al
    Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and nevi in vivo.
    Br J Dermatol. 2015 Nov 28. doi: 10.1111/bjd.14323.
    PubMed     Text format     Abstract available


  117. MONCRIEFF M, Fadhil M, Garrioch J
    Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience.
    Br J Dermatol. 2015 Nov 24. doi: 10.1111/bjd.14314.
    PubMed     Text format     Abstract available


  118. GUIDA S, Pellacani G, Cesinaro AM, Moscarella E, et al
    Spitz naevi and melanomas with similar dermoscopic pattern: can confocal microscopy differentiate?
    Br J Dermatol. 2015 Nov 11. doi: 10.1111/bjd.14286.
    PubMed     Text format     Abstract available


  119. SEBARATNAM DF, Anforth R, Fernandez-Penas P
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma.
    Br J Dermatol. 2015 Nov 2. doi: 10.1111/bjd.14264.
    PubMed     Text format     Abstract available


    October 2015
  120. RIBERO S, Zugna D, Osella-Abate S, Glass D, et al
    Prediction of high naevus count in a healthy UK population to estimate melanoma risk.
    Br J Dermatol. 2015 Oct 19. doi: 10.1111/bjd.14216.
    PubMed     Text format     Abstract available


    September 2015
  121. MOSER J, Moshammer R, Koglbauer G, Kitzwogerer M, et al
    Sentinel-node biopsy in melanoma: A single center experience with 216 consecutive patients.
    Br J Dermatol. 2015 Sep 24. doi: 10.1111/bjd.14189.
    PubMed     Text format     Abstract available


  122. ZARAGOZA J, Caille A, Beneton N, Bens G, et al
    Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
    Br J Dermatol. 2015 Sep 6. doi: 10.1111/bjd.14155.
    PubMed     Text format     Abstract available


  123. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.
    Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152.
    PubMed     Text format     Abstract available


  124. KRAFT S, Tsao H
    Melanoma-associated naevi: precursors or coincidence?
    Br J Dermatol. 2015;173:633-4.
    PubMed     Text format    


  125. SCHOFIELD JK
    Sentinel lymph node biopsy: in support of equity of access, informed shared decision making and patient choice.
    Br J Dermatol. 2015;173:863-4.
    PubMed     Text format    


    August 2015
  126. CHAVEZ-BOURGEOIS M, Iglesias P, Brito J, Malvehy J, et al
    Skin cancers detected as casual findings with Reflectance Confocal Microscopy (RCM) in the assessment of melasma treatment.
    Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14066.
    PubMed     Text format     Abstract available


  127. MONCRIEFF M, Garioch J
    MSLT-I: it's all about the lymph nodes....
    Br J Dermatol. 2015;173:626-7.
    PubMed     Text format    


  128. MCGREGOR JM, Sasieni P
    MSLT-I: it's all about the lymph nodes...: reply from the authors.
    Br J Dermatol. 2015;173:627-8.
    PubMed     Text format    


    July 2015
  129. BENATI E, Argenziano G, Kyrgidis A, Moscarella E, et al
    Melanoma and naevi with globular pattern: Confocal microscopy as an aid for diagnostic differentiation.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14049.
    PubMed     Text format     Abstract available


  130. LALLAS A, Kyrgidis A, Koga H, Moscarella E, et al
    The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14045.
    PubMed     Text format     Abstract available


  131. LI Z, Wang Z, Yu Y, Zhang H, et al
    Smoking is Inversely Related to Cutaneous Malignant Melanoma -Says Results from a Meta-analysis.
    Br J Dermatol. 2015 Jul 2. doi: 10.1111/bjd.13998.
    PubMed     Text format     Abstract available


  132. DAVIES MA
    BRAF in early stage melanoma: rationale for testing and treatment?
    Br J Dermatol. 2015;173:9-10.
    PubMed     Text format    


  133. GOHARA M
    Skin cancer: an African perspective.
    Br J Dermatol. 2015;173 Suppl 2:17-21.
    PubMed     Text format     Abstract available


    June 2015
  134. SINHA R, Larkin J, Gore M, Fearfield L, et al
    Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Br J Dermatol. 2015 Jun 24. doi: 10.1111/bjd.13958.
    PubMed     Text format     Abstract available


  135. BENATI E, Zalaudek I, Piana S, Argenziano G, et al
    In vivo detection of peripheral clefting in melanocytic lesions.
    Br J Dermatol. 2015 Jun 23. doi: 10.1111/bjd.13959.
    PubMed     Text format     Abstract available


  136. FINNANE A, Soyer HP
    Smartphone diagnosis of skin cancer: there's not yet an app for that.
    Br J Dermatol. 2015;172:1474-5.
    PubMed     Text format    


  137. WU S
    Do mutations in BRCA1/BRCA2 confer a higher risk of skin cancer?
    Br J Dermatol. 2015;172:1473.
    PubMed     Text format    


  138. GUMASTE PV, Penn LA, Cymerman RM, Kirchhoff T, et al
    Skin cancer risk in BRCA1/2 mutation carriers.
    Br J Dermatol. 2015;172:1498-506.
    PubMed     Text format     Abstract available


  139. VIGARIOS E, Lamant L, Delord JP, Fricain JC, et al
    Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Br J Dermatol. 2015;172:1680-2.
    PubMed     Text format    


    May 2015
  140. THOMAS L
    Dermoscopy for melanoma: don't forget to take a photo.
    Br J Dermatol. 2015;172:1182-3.
    PubMed     Text format    


    April 2015
  141. OAKLEY AM
    Mobile teledermatology is here to stay.
    Br J Dermatol. 2015;172:856-7.
    PubMed     Text format    


  142. MANAHAN MN, Soyer HP, Loescher LJ, Horsham C, et al
    A pilot trial of mobile, patient-performed teledermoscopy.
    Br J Dermatol. 2015;172:1072-80.
    PubMed     Text format     Abstract available


  143. DEBARBIEUX S, Gaspar R, Depaepe L, Dalle S, et al
    Intraoperative diagnosis of nonpigmented nail tumours with ex vivo fluorescence confocal microscopy: 10 cases.
    Br J Dermatol. 2015;172:1037-44.
    PubMed     Text format     Abstract available


    January 2015
  144. LONGO C, Moscarella E, Argenziano G, Lallas A, et al
    Reflectance confocal microscopy in the diagnosis of solitary pink skin tumors: Review of Diagnostic Clues.
    Br J Dermatol. 2015 Jan 30. doi: 10.1111/bjd.13689.
    PubMed     Text format     Abstract available


  145. JEUDY G, Dalac-Rat S, Bonniaud B, Hervieu A, et al
    Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Br J Dermatol. 2015;172:1454-5.
    PubMed     Text format    


  146. RICHTIG E, Arzberger E, Hofmann-Wellenhof R, Fink-Puches R, et al
    Assessment of changes in lentigo maligna during radiotherapy by in-vivo reflectance confocal microscopy: a pilot study.
    Br J Dermatol. 2015;172:81-7.
    PubMed     Text format     Abstract available


    August 2014
  147. MOSCARELLA E, Al Jalbout S, Piana S, Argenziano G, et al
    The stars within the melanocytic garden: Unusual variants of Spitz nevi.
    Br J Dermatol. 2014 Aug 13. doi: 10.1111/bjd.13347.
    PubMed     Text format     Abstract available


  148. LAWRENCE CM, Rahim R, Charlton F, Husain A, et al
    Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results.
    Br J Dermatol. 2014;171:298-303.
    PubMed     Text format     Abstract available


    July 2014
  149. BRUGIERE C, Stefan A, Morice C, Cornet E, et al
    Vemurafenib skin phototoxicity is indirectly linked to UVA-MED decrease.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13300.
    PubMed     Text format     Abstract available


    May 2014
  150. PELLACANI G, Pepe P, Casari A, Longo C, et al
    Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study.
    Br J Dermatol. 2014 May 29. doi: 10.1111/bjd.13148.
    PubMed     Text format     Abstract available


    April 2014
  151. KOSE K, Cordova M, Duffy M, Flores ES, et al
    Video-Mosaicing of Reflectance Confocal Images For Examination of Extended Areas of Skin In Vivo.
    Br J Dermatol. 2014 Apr 10. doi: 10.1111/bjd.13050.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: